Trial Profile
Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Rilonacept (Primary)
- Indications Pericarditis
- Focus Registrational; Therapeutic Use
- Acronyms RHAPSODY
- Sponsors Kiniksa Pharmaceuticals
- 13 Nov 2023 Results of sub-group analysis presented at the American Heart Association Scientific Sessions 2023.
- 07 Nov 2022 Results assessing efficacy, safety, and clinical decision making presented at the American Heart Association Scientific Sessions 2022
- 07 Nov 2022 Results assessing efficacy of the interleukin (IL)-1 antagonist rilonacept in treating and preventing recurrence could inform COVID-19 disease and vaccination management presented at the American Heart Association Scientific Sessions 2022